Jump to content

Onartuzumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 01:18, 9 September 2016 (Updating {{infobox_drug}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'Watchedfields') per Chem/infobox_drug validation (report errors or bugs)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Onartuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetscatter factor receptor kinase
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC4422H6820N1168O1363S31
Molar mass99.1 kg/mol g·mol−1
 ☒NcheckY (what is this?)  (verify)

Onartuzumab is a humanized monoclonal antibody designed for the treatment of cancer.[1]

Onartuzumab was developed by Genentech, Inc.

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab" (PDF). American Medical Association.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Onartuzumab&oldid=738450410"